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To the editor,
I read with great interest the recent article by Rao and Go regarding new treatment 
options for the management of constipation in the elderly.1 In this article, alvi-
mopan was described as having been “recently…introduced for the treatment of 
opioid-induced constipation”. Furthermore, alvimopan was included in a treatment 
algorithm for   management of opioid-induced chronic constipation in the elderly 
(see Figure 1 in Rao and Go).1 Additionally, other “potential uses” for peripherally 
acting mu-opioid receptor antagonists (including alvimopan) were identified by the 
authors and included treatment of “opioid-related nausea and vomiting, urinary reten-
tion, pruritus or   post-operative ileus”. This characterization of alvimopan requires 
further clarification.
Alvimopan was approved by the US Food and Drug Administration (FDA) in 
2008 for the acceleration of gastrointestinal recovery following partial small or large 
bowel resection with primary anastomosis.2 Alvimopan has not been approved for 
any other indication, such as treatment of opioid-induced constipation. Importantly, 
the Warnings and Precautions section of the label describes the potential adverse 
effects that may be associated with administration of alvimopan 12 mg to patients 
recently exposed to opioids. Furthermore, alvimopan is approved only for short-term, 
in-hospital use, and hospitals dispensing alvimopan must register in and meet all 
of the requirements of the Entereg® Access Support and Education (E.A.S.E.™) 
Program.3
It is important that your readers understand these facts about alvimopan use in 
light of the information provided by Rao and Go.1
Disclosure
Lee Techner, DPM, is the Vice President of Medical Affairs and Pharmacovigilance/
Drug Safety at Adolor Corporation, the company that developed and is comarketing 
Entereg® (alvimopan).
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